Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.49 |
| ▸ | MC3R | P41968 | 2/20 | 0.49 |
| ▸ | MC1R | Q01726 | 2/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488227 | 0.78 | HTR6 (0.54) | — | |
| SCHEMBL8565864 | 0.78 | MC4R (0.46) | MC4RMC3RMC1RSCD5GABRA1 | |
| SCHEMBL3764570 | 0.78 | HTR6 (0.54) | — | |
| SCHEMBL11466316 | 0.78 | MC4R (0.46) | MC4RMC3RMC1RSCD5GABRA1 | |
| SCHEMBL23459127 | 0.77 | SCD5 (0.57) | MC4RMC3RMC1RSCD5GABRA1 | |
| SCHEMBL4151234 | 0.77 | MC4R (0.43) | MC4RMC3RMC1RSCD5GABRA1 | |
| SCHEMBL11371130 | 0.77 | ABHD6 (0.43) | MC4RMC3RMC1RSCD5GABRA1 | |
| SCHEMBL908981 | 0.77 | SCD5 (0.57) | MC4RMC3RMC1RSCD5GABRA1 | |
| SCHEMBL4151231 | 0.77 | MC4R (0.46) | MC4RMC3RMC1RSCD5ATM | |
| SCHEMBL5530480 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | claimed |
| EP-1737841-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | Astellas Pharma Inc. (JP) | 2007-01-03 | — | — | EP | claimed |
| WO-2005095384-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-10-13 | — | — | WO | claimed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | claimed |
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1737841-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | Astellas Pharma Inc. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005095384-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | MC4R 369/4885MC3R 299/4885MC1R 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.